	US 12,286,404 B2
	Solid state forms of Mitapivat and process for preparation thereof
Polina Lapido, Rishon LeZion (IL); Doron Rudik, Modi'in (IL); and Ofir Shaul, Hod Hasharon (IL)
Appl. No. 17/794,693
Filed by TEVA PHARMACEUTICALS INTERNATIONAL GMBH, Jona (CH)
PCT Filed Jan. 28, 2021, PCT No. PCT/US2021/015477 § 371(c)(1), (2) Date Jul. 22, 2022, PCT Pub. No. WO2021/154987, PCT Pub. Date Aug. 5, 2021.
Claims priority of provisional application 63/054,930, filed on Jul. 22, 2020.
Claims priority of provisional application 63/028,028, filed on May 21, 2020.
Claims priority of provisional application 63/013,715, filed on Apr. 22, 2020.
Claims priority of provisional application 62/991,186, filed on Mar. 18, 2020.
Claims priority of provisional application 62/991,172, filed on Mar. 18, 2020.
Claims priority of provisional application 62/966,687, filed on Jan. 28, 2020.
Prior Publication US 2023/0098234 A1, Mar. 30, 2023
Int. Cl. C07D 215/36 (2006.01)

CPC C07D 215/36 (2013.01) [C07B 2200/13 (2013.01)]

16 Claims

1. A crystalline product of Mitapivat hemisulfate and an ascorbic acid co-former, wherein the crystalline product is characterized by an XRPD pattern having peaks at 8.9, 13.3, 14.9, 15.9, and 20.5 degrees 2-theta±0.2 degrees 2-theta.